The Vanguard Group 13D and 13G filings for Sangamo Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-12 4:53 pm Unchanged |
2024-09-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 9,597,642 4.600% |
0 (Unchanged) |
Filing |
| 2024-11-04 1:54 pm Sale |
2024-09-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 9,597,642 4.600% |
-3,001,352 (-23.82%) |
Filing |
| 2024-02-13 5:13 pm Sale |
2023-12-29 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 12,598,994 7.100% |
-1,446,615 (-10.30%) |
Filing |
| 2023-02-09 11:32 am Purchase |
2022-12-30 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 14,045,609 8.570% |
4,705,054 (+50.37%) |
Filing |
| 2022-02-10 08:37 am Purchase |
2021-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 9,340,555 6.410% |
886,897 (+10.49%) |
Filing |
| 2021-02-10 11:52 am Sale |
2020-12-31 | 13G | Sangamo Therapeutics, Inc. SGMO |
The Vanguard Group | 8,453,658 5.980% |
-34,846 (-0.41%) |
Filing |